Global Search

Search articles, concepts, and chapters

Graefes Arch Clin Exp OphthalmolJune 201515 citations

Risk factors for depressive symptoms in glaucoma patients: a nationwide case-control study.

Su Chien-Chia, Chen Judy Yi-Chu, Wang Tsing-Hong, Huang Jehn-Yu, Yang Chung-May, Wang I-Jong


AI Summary

This study found that in glaucoma patients, higher comorbidity burden, particularly with systemic beta-blockers and calcium channel blockers, significantly increases depression risk, not topical glaucoma medications.

Abstract

Purpose

The purpose was to investigate the risk factors for depressive symptoms in glaucoma patients.

Methods

From the Longitudinal Health Insurance Database in Taiwan, we included 1190 glaucoma patients with subsequent depression diagnoses in the case group and randomly selected 4673 glaucoma patients without depression diagnoses as the control group, matched by age, sex, and time of glaucoma diagnosis. The age-adjusted Charlson comorbidity index (ACCI) score was used to compute the burden of comorbidity for each patient. Current use (past 6 months) of topical antiglaucoma medications and systemic medications was identified. Multivariate regression was used to analyze the risk factors for depression.

Results

The mean age for glaucoma patients was 61.88 years. Patients with depressive symptoms had significantly higher ACCI scores (P < .0001). The current use of any topical antiglaucoma medications was not associated with an increased risk for depression. However, higher ACCI scores (P < .0001), cerebrovascular diseases (odds ratio [OR] = 1.324, 95 % confidence interval [CI] = 1.118--1.568), dementia (OR = 2.647, 95 % CI = 2.142-3.270), thyroid diseases (OR = 1.720, 95 % CI = 1.366-2.165), headaches (OR = 1.299, 95 % CI = 1.112-1.518), and current use of systemic β-blockers (OR = 1.782, 95 % CI = 1.538-2.065) and calcium channel blockers (OR = 1.396, 95 % CI, 1.197-1.629) were found to increase the risk of depression in glaucoma patients.

Conclusions

In this study, a comorbidity burden was a significant risk factor for depression in glaucoma patients, particularly for those currently using systemic β-blockers and calcium channel blockers.


MeSH Terms

AdultAgedAntihypertensive AgentsCardiovascular DiseasesCase-Control StudiesCerebrovascular DisordersComorbidityDatabases, FactualDepressive DisorderDiabetes ComplicationsFemaleGlaucomaHumansHypertensionMaleMiddle AgedOdds RatioPeripheral Vascular DiseasesRisk FactorsTaiwan

Key Concepts3

In a nationwide case-control study in Taiwan, glaucoma patients with depressive symptoms had significantly higher age-adjusted Charlson comorbidity index (ACCI) scores (P < .0001) compared to glaucoma patients without depression.

PrognosisCohortNationwide case-control studyn=1190 glaucoma patients with depressio…Ch1Ch10

In a nationwide case-control study in Taiwan, higher age-adjusted Charlson comorbidity index (ACCI) scores (P < .0001), cerebrovascular diseases (odds ratio [OR] = 1.324, 95 % confidence interval [CI] = 1.118-1.568), dementia (OR = 2.647, 95 % CI = 2.142-3.270), thyroid diseases (OR = 1.720, 95 % CI = 1.366-2.165), headaches (OR = 1.299, 95 % CI = 1.112-1.518), and current use of systemic β-blockers (OR = 1.782, 95 % CI = 1.538-2.065) and calcium channel blockers (OR = 1.396, 95 % CI, 1.197-1.629) were found to increase the risk of depression in glaucoma patients.

PrognosisCohortNationwide case-control studyn=1190 glaucoma patients with depressio…Ch1Ch10Ch28

In a nationwide case-control study in Taiwan, current use (past 6 months) of any topical antiglaucoma medications was not associated with an increased risk for depression in glaucoma patients.

PrognosisCohortNationwide case-control studyn=1190 glaucoma patients with depressio…Ch1Ch29

Is this article assigned to the wrong chapter(s)? Let us know.